Table 6 Treatment uptake in study cohorts receiving opioid substitution therapy

Cournot et al, 2004

31% of antibody+ (23/75)

Intent-to-treat: 36% (11/31)¹

47% of RNA+ (23/49)

72% of other (23/32)

Cullen et al, 2007

3% of antibody+ (3/104)

NA

10% of RNA+ (3/29)

Schulte et al, 2010²

9% of antibody+ (26/301)

Intent-to-treat: 69% (18/26)

As-treated: 86% (18/21)

Witteck et al, 2011²

15% of RNA+ (29/193)

Intent-to-treat: 52% (13/25)